–
Статьи в журналах
-
- 2020 Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- Finn Richard S., Ryoo Baek-Yeol, Merle Philippe, Kudo Masatoshi, Bouattour Mohamed, Lim Ho Yeong, Breder Valeriy, Edeline Julien, Chao Yee, Ogasawara Sadahisa, Yau Thomas, Garrido Marcelo, Chan Stephen L., Knox Jennifer, Daniele Bruno, Ebbinghaus Scot W., Chen Erluo, Siegel Abby B., Zhu Andrew X., Cheng Ann-Lii
- в журнале Journal of Clinical Oncology, издательство American Society of Clinical Oncology (United States), том 38, № 3, с. 193-202 DOI
-
- 2020 Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
- Ryoo Baek-Yeol, Merle Philippe, Kulkarni Amit S., Cheng Ann-Lii, Bouattour Mohamed, Lim Ho Yeong, Breder Valeriy, Edeline Julien, Chao Yee, Ogasawara Sadahisa, Yau Thomas, Garrido Marcelo, Chan Stephen L., Daniele Bruno, Norquist Josephine M., Chen Erluo, Siegel Abby B., Zhu Andrew X., Finn Richard S., Kudo Masatoshi
- в журнале Cancer, издательство John Wiley & Sons Inc. (United States), том 127, № 6, с. 865-874 DOI